A new trading day began on Friday, with Denali Therapeutics Inc (NASDAQ: DNLI) stock price down -3.33% from the previous day of trading, before settling in for the closing price of $21.32. DNLI’s price has ranged from $14.56 to $33.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 264.19% over the last five years. Meanwhile, its annual earnings per share averaged -164.91%. With a float of $124.63 million, this company’s outstanding shares have now reached $143.84 million.
The firm has a total of 445 workers. Let’s measure their productivity. In terms of profitability, gross margin is 102.06%, operating margin of 165.42%, and the pretax margin is 140.13%.
Denali Therapeutics Inc (DNLI) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Denali Therapeutics Inc is 13.40%, while institutional ownership is 88.48%. The most recent insider transaction that took place on Nov 11 ’24, was worth 1,932,665. In this transaction Director of this company sold 59,441 shares at a rate of $32.51, taking the stock ownership to the 9,220 shares. Before that another transaction happened on Nov 07 ’24, when Company’s COFO and Secretary sold 15,558 for $29.91, making the entire transaction worth $465,286. This insider now owns 178,066 shares in total.
Denali Therapeutics Inc (DNLI) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -164.91% per share during the next fiscal year.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Here are Denali Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.76, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -2.94 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Analysing the last 5-days average volume posted by the [Denali Therapeutics Inc, DNLI], we can find that recorded value of 1.05 million was lower than the volume posted last year of 1.06 million. As of the previous 9 days, the stock’s Stochastic %D was 12.57%. Additionally, its Average True Range was 1.13.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 0.93%, which indicates a significant decrease from 2.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.02% in the past 14 days, which was lower than the 52.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $25.37, while its 200-day Moving Average is $23.09. Now, the first resistance to watch is $21.33. This is followed by the second major resistance level at $22.04. The third major resistance level sits at $22.45. If the price goes on to break the first support level at $20.20, it is likely to go to the next support level at $19.78. Now, if the price goes above the second support level, the third support stands at $19.07.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
With a market capitalization of 2.87 billion, the company has a total of 143,922K Shares Outstanding. Currently, annual sales are 330,530 K while annual income is -145,220 K. The company’s previous quarter sales were 0 K while its latest quarter income was -107,190 K.
